AstraZeneca PLC (AZN)

10,600.0
+2.0(+0.02%)
  • Volume:
    1,408,386
  • Bid/Ask:
    10,232.0/10,700.0
  • Day's Range:
    10,514.0 - 10,646.0

AZN Overview

Prev. Close
10,598
Day's Range
10,514-10,646
Revenue
30.66B
Open
10,574
52 wk Range
7,870-11,000
EPS
-0.53
Volume
1,408,386
Market Cap
164B
Dividend (Yield)
210.10
(1.98%)
Average Vol. (3m)
2,431,673
P/E Ratio
-
Beta
0.31
1-Year Change
30.04%
Shares Outstanding
1,549,464,013
Next Earnings Date
Jul 28, 2022
What is your sentiment on AstraZeneca?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC News

AstraZeneca PLC Analysis

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Employees
83100

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong BuyBuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Pfizer and Moderna fell big time in share prices, while Astra kept it’s stable 9ish. How?
    0
    • it's at 10k now
      0
  • An attractive PRE-IPO called SpectrumX based in England plans to launch by November and i'm very hopeful of this particular investment. Clinical trials for their Covid-19 respiratory treatment are now in phase 2 of development which will be a game changer once hospitals get their hands on it. This will not be factored into the company valuation when listed. So if the trials are successful the market value will rocket. Thats why im seriously excited about this IPO and i don't usually go near PRE IPO's.
    4
    • how's it doing today
      0
    • how's it doing today
      0
  • 50
    0
    • *50000
      0
  • 19970410🌍 10000%
    0
    • Most of vunerable demographic now vaccinated. Will younger people accept the jab or will potential health concerns outweigh the potential benefits. I'm short AstraZeneca
      5
      • net short positions available on the PNC Borsa app
        0
        • Above 7500 to 9750 soon these weeks bullish sentiments business development infrastructure expenditures stimulus package cause its stance growth economics of scales
          2
          • you are nostetadamoos
            1
        • may be buy or sell the stock but be very cautious before being vaccinated : some serious cases in Europe especially with young to intermediate people
          11
          • GP GAPYes Im chief nurse teacher in a very big hospital. Not specialised in vaccine but i know a little bit about heath. And im a pro vaccine. But the rule we were givenby health autorities  was : Astra not for people under 55.
            1
          • Thanks for the advise.
            0
          • Jenny Goughlike dada
            0
        • This is moving now....at last! US approval coming.
          1
          • The cause behind the suspected vaccine side effects has been found. This is the opinion of a Norwegian expert group that examined the three healthcare employees who were admitted to hospital after being vaccinated with Astra Zeneca's vaccine. The vaccine triggered a strong immune reaction in the people. - I see no other reason than that it is the vaccine that triggers it, says the chief physician and professor Pål Andre Holme to VG. Sell off coming
            5
            • I guess that puts this Professor at odds with all the others looking at the data then.   Strange they were all healthcare employees.
              0
            • u shorting?
              1